Cyclic AMP

Cyclic adenosine monophosphate (cAMP, 3',5'-cyclic adenosine monophosphate; formula C₁₀H₁₂N₅O₆P, molar mass 329.21 g mol⁻¹) is a cyclic nucleotide derivative of adenosine triphosphate (ATP) in which the single phosphate group is esterified simultaneously to both the 3'-hydroxyl and 5'-hydroxyl oxygen atoms of the ribose sugar ring, forming a cyclic phosphodiester bond. Discovered in 1957 by Earl W. Sutherland Jr. and Ted Rall while investigating how epinephrine and glucagon stimulate hepatic glycogen breakdown in cell-free liver homogenates (work awarded the 1971 Nobel Prize in Physiology or Medicine), cAMP established the foundational paradigm of second-messenger signal transduction: extracellular hydrophilic hormones and neurotransmitters ("first messengers") that cannot cross the cell membrane bind cell-surface G-protein-coupled receptors (GPCRs) to regulate intracellular synthesis of a diffusible small molecule ("second messenger") that coordinates metabolic enzymes, ion channels, and gene transcription.

Gα_s vs. Gα_i Regulation of Adenylyl Cyclase (AC1–AC10)

Intracellular cAMP concentrations (which sit near ~0.1 μM in resting mammalian cells and rise 5- to 20-fold to 1–2 μM within seconds of hormone stimulation) are governed by the dynamic enzymatic balance between adenylyl cyclase (AC, EC 4.6.1.1) synthesis and cyclic nucleotide phosphodiesterase (PDE, EC 3.1.4.17) degradation:

1. Adenylyl Cyclase Synthesis: In the presence of Mg²⁺ (or Mn²⁺) cofactors, adenylyl cyclase catalyzes an intramolecular nucleophilic attack by the ribose 3'-OH group on the α-phosphorus atom of Mg-ATP, releasing 3',5'-cAMP and inorganic pyrophosphate (PP_i, which inorganic pyrophosphatase rapidly hydrolyzes to 2 P_i, Δ*G*°' ≈ −19 kJ mol⁻¹, driving the cyclization reaction forward):

Mammals express nine transmembrane adenylyl cyclase isoforms (AC1–AC9)—each comprising two 6-transmembrane bundles (M₁ and M₂) and two cytoplasmic catalytic domains (C_1a and C_2a) that assemble into a pseudosymmetric catalytic cleft—plus one soluble bicarbonate/Ca²⁺-activated isoform (sAC / AC10). When an extracellular agonist (such as epinephrine at β-adrenergic receptors, glucagon, TSH, ACTH, LH, vasopressin at V₂ receptors, or dopamine at D₁ receptors) activates a Gα_s-coupled GPCR, GTP-bound Gα_s binds the C₂/C₁ interface to stabilize the closed, catalytically active conformation (a state also locked open directly by the plant diterpene forskolin). Conversely, agonists of Gα_i/o-coupled GPCRs (such as α₂-adrenergic, opioid μ, muscarinic M₂/M₄, or dopamine D₂ receptors) release Gα_i-GTP, which binds the opposite face of the C₁ domain to inhibit cAMP synthesis.

1. Phosphodiesterase (PDE) Termination and Subcellular Microdomains: Cyclic AMP signaling is terminated by phosphodiesterases (PDE1–PDE11), binuclear Zn²⁺/Mg²⁺ metallohydrolases that cleave the high-energy 3'-phosphodiester bond (Δ*G*°' ≈ −48 kJ mol⁻¹) to yield inactive 5'-AMP:

Rather than diffusing uniformly across the entire cytosol, cAMP is sculpted into nanometer-scale subcellular microdomains anchored by A-kinase anchoring proteins (AKAPs), which tether PKA holoenzymes alongside specific PDE4/PDE3 isoforms and protein phosphatases directly at target substrates (such as cardiac L-type Ca²⁺ channels CACNA1C or the sarcoplasmic reticulum phospholamban complex). Methylxanthines (caffeine, theophylline) act as non-selective PDE inhibitors, whereas rolipram and roflumilast selectively inhibit cAMP-specific PDE4 to suppress airway inflammation in chronic obstructive pulmonary disease (COPD).

Two classic bacterial AB₅ exotoxins hijack heterotrimeric G-protein control of the cAMP pathway by covalent ADP-ribosylation using cellular NAD⁺ as a substrate:

1. Cholera Toxin (Vibrio cholerae): The enzymatic A1 subunit catalyzes the transfer of an ADP-ribose group from NAD⁺ onto Arg201 in the GTPase active site of Gα_s. This abolishes the intrinsic GTPase activity of Gα_s, locking Gα_s permanently in its active GTP-bound state. In intestinal crypt enterocytes, runaway adenylyl cyclase activity drives a 100-fold surge in intracellular cAMP, causing PKA to hyper-phosphorylate and open apical CFTR chloride channels while inhibiting Na⁺/H⁺ exchangers—resulting in massive secretory efflux of Cl⁻, Na⁺, and osmotic water into the gut lumen (up to 10–20 liters per day of "rice-water" diarrhea).
2. Pertussis Toxin (Bordetella pertussis): Catalyzes the ADP-ribosylation of a conserved C-terminal cysteine residue (Cys351) on the inhibitory Gα_i/o subunit. Modified Gα_i-GDP can no longer interact with activated GPCRs to release its brake on adenylyl cyclase, leaving cellular cAMP uninhibited (while bacterial CyaA calmodulin-activated adenylyl cyclase toxin directly floods host phagocytes with supraphysiological cAMP to paralyze chemotaxis and oxidative burst).

How can the same second messenger (cAMP) trigger glycogen breakdown in a liver cell, increased heart rate in a pacemaker cell, and water reabsorption in a kidney cell?

Cellular specificity arises from two layers: (1) receptor repertoire (only cells expressing glucagon receptors respond to glucagon, whereas only cells expressing V₂ vasopressin receptors respond to ADH), and (2) cell-type-specific downstream substrates and AKAP scaffolding. In a hepatocyte, PKA phosphorylates phosphorylase kinase and CREB to drive glycogenolysis and gluconeogenesis; in a sinoatrial node cardiomyocyte, cAMP binds directly to HCN4 pacemaker channels and PKA phosphorylates Ca_V1.2 and phospholamban; and in a renal collecting duct cell, PKA phosphorylates Ser256 on Aquaporin-2 vesicles.

Why is cyclic AMP used as a hunger signal in bacteria (E. coli) and social amoebae (Dictyostelium)?

Across evolutionary history, cyclic AMP originated as an ancient nutritional stress signal before being co-opted for metazoan hormone signaling. In Escherichia coli, when extracellular glucose is abundant, the phosphotransferase system (PTS) enzyme EIIA^Glc is dephosphorylated as it imports glucose; when glucose runs out, phosphorylated EIIA^Glc~P accumulates and activates bacterial adenylyl cyclase (cyaA), raising cytosolic cAMP so the cAMP–CAP complex can activate alternative sugar operons (such as the lac operon). Even more dramatically, when unicellular amoebae of the slime mold Dictyostelium discoideum starve, they secrete rhythmic extracellular waves of cAMP that act as a chemoattractant via cell-surface cAMP GPCRs (cAR1), guiding 100,000 solitary amoebae to stream together into a multicellular fruiting body.

What is the difference between cAMP and cGMP signaling?

Whereas 3',5'-cAMP is synthesized from ATP by G-protein-regulated adenylyl cyclases and activates PKA and EPAC, 3',5'-cyclic guanosine monophosphate (cGMP) is synthesized from GTP by either soluble guanylyl cyclase (sGC)—a heme-containing cytoplasmic enzyme activated by the gaseous vasodilator nitric oxide (NO)—or particulate (transmembrane) guanylyl cyclases (NPR-A / NPR-B) activated by cardiac atrial and brain natriuretic peptides (ANP / BNP). cGMP activates protein kinase G (PKG) to relax vascular smooth muscle (lowering blood pressure; potentiated by PDE5 inhibitors such as sildenafil) and gates CNG cation channels in retinal rod and cone photoreceptors during visual phototransduction.

1. Rall, T. W., & Sutherland, E. W. (1958). "Formation of a cyclic adenine ribonucleotide by tissue particles." Journal of Biological Chemistry, 232(2), 1065–1076. https://doi.org/10.1016/S0021-9258(19)77422-577422-5)
2. Taylor, S. S., Ilouz, R., Zhang, P., & Kornev, A. P. (2012). "Assembly of allosteric macromolecular switches: lessons from PKA." Nature Reviews Molecular Cell Biology, 13(10), 646–658. https://doi.org/10.1038/nrm3432
3. de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998). "Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP." Nature, 396(6710), 474–477. https://doi.org/10.1038/24884
4. Zaccolo, M., Zerio, A., & Lobo, M. J. (2021). "Subcellular organization of the cAMP signaling pathway." Pharmacological Reviews, 73(1), 278–309. https://doi.org/10.1124/pharmrev.120.000086